A Study of Camizestrant in ER+/HER2- Early Breast Cancer After at Least 2 Years of Standard Adjuvant Endocrine Therapy
Status: RECRUITING
Study type: INTERVENTIONAL
Conditions: Breast Cancer, Early Breast Cancer
Interventions: DRUG: Camizestrant|DRUG: Tamoxifen|DRUG: Anastrozole|DRUG: Letrozole|DRUG: Exemestane
Sponsor: AstraZeneca